Gan & Lee Pharmaceuticals Co Ltd (603087) - Total Assets
Based on the latest financial reports, Gan & Lee Pharmaceuticals Co Ltd (603087) holds total assets worth CN¥12.14 Billion CNY (≈ $1.78 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Gan & Lee Pharmaceuticals Co Ltd (603087) net assets for net asset value and shareholders' equity analysis.
Gan & Lee Pharmaceuticals Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's total assets have evolved over time, based on quarterly financial data.
Gan & Lee Pharmaceuticals Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Gan & Lee Pharmaceuticals Co Ltd's total assets of CN¥12.14 Billion consist of 31.5% current assets and 68.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.5% |
| Accounts Receivable | CN¥248.57 Million | 2.1% |
| Inventory | CN¥1.05 Billion | 8.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.19 Billion | 9.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gan & Lee Pharmaceuticals Co Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gan & Lee Pharmaceuticals Co Ltd's current assets represent 31.5% of total assets in 2024, a decrease from 60.7% in 2013.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, down from 27.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 20.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 9.9% of total assets.
Gan & Lee Pharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Gan & Lee Pharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$5.82 Billion |
|
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026
|
China | CN¥1.75 Billion |
|
Osteopore Ltd
AU:OSX
|
Australia | AU$4.19 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
Gan & Lee Pharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.20 | 8.04 | 14.54 |
| Quick Ratio | 5.57 | 6.77 | 13.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.28 Billion | CN¥5.68 Billion | CN¥5.55 Billion |
Gan & Lee Pharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Gan & Lee Pharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.37 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 2.8% |
| Total Assets | CN¥12.04 Billion |
| Market Capitalization | $5.26 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Gan & Lee Pharmaceuticals Co Ltd's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Gan & Lee Pharmaceuticals Co Ltd's assets grew by 2.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Gan & Lee Pharmaceuticals Co Ltd (2013–2024)
The table below shows the annual total assets of Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥12.04 Billion ≈ $1.76 Billion |
+2.80% |
| 2023-12-31 | CN¥11.72 Billion ≈ $1.71 Billion |
+10.45% |
| 2022-12-31 | CN¥10.61 Billion ≈ $1.55 Billion |
-2.27% |
| 2021-12-31 | CN¥10.85 Billion ≈ $1.59 Billion |
+14.15% |
| 2020-12-31 | CN¥9.51 Billion ≈ $1.39 Billion |
+57.76% |
| 2019-12-31 | CN¥6.03 Billion ≈ $881.89 Million |
+28.37% |
| 2018-12-31 | CN¥4.69 Billion ≈ $687.01 Million |
+25.42% |
| 2017-12-31 | CN¥3.74 Billion ≈ $547.77 Million |
+43.76% |
| 2016-12-31 | CN¥2.60 Billion ≈ $381.03 Million |
+43.77% |
| 2015-12-31 | CN¥1.81 Billion ≈ $265.03 Million |
+50.62% |
| 2014-12-31 | CN¥1.20 Billion ≈ $175.96 Million |
+44.43% |
| 2013-12-31 | CN¥832.55 Million ≈ $121.83 Million |
-- |
About Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more